Vera Therapeutics (VERA) Operating Leases (2020 - 2025)

Vera Therapeutics (VERA) has 6 years of Operating Leases data on file, last reported at $1.9 million in Q4 2025.

• Quarterly Operating Leases fell 22.24% year-over-year to $1.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.9 million (down 22.24% YoY) and the FY2025 annual result came in at $1.9 million, down 22.24% from the prior year.
• Operating Leases slipped to $1.9 million in Q4 2025, from $2.1 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $5.4 million in Q1 2022 to a low of $455000.0 in Q2 2024.
• A 5-year average of $2.4 million and a median of $2.2 million in 2025 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2024 — Operating Leases plunged 82.3% — and 2025, when it surged 390.77%.
• Tracing VERA's Operating Leases over 5 years: stood at $1.4 million in 2021, then soared by 181.28% to $3.8 million in 2022, then plunged by 63.59% to $1.4 million in 2023, then soared by 76.92% to $2.5 million in 2024, then dropped by 22.24% to $1.9 million in 2025.
• The last three Operating Leases figures came in at $1.9 million (Q4 2025), $2.1 million (Q3 2025), and $2.2 million (Q2 2025), per Business Quant data.